What is the next appropriate management for a 52-year-old man with erectile dysfunction, a dorsal penile plaque causing curvature less than 30°, normal cavernous arterial flow, mild venous leak, and no response to oral vitamin E?

Oral PDE-5 Inhibitor (Answer: A)

For this patient with stable Peyronie's disease (curvature <30°), erectile dysfunction, and mild venous leak, the next step is an oral PDE-5 inhibitor to address both the erectile dysfunction and potentially improve the Peyronie's disease symptoms.

Clinical Reasoning

This 52-year-old man presents with:

• Stable Peyronie's disease (18 months duration, curvature <30°)
• Erectile dysfunction with mild venous leak
• Failed conservative therapy (vitamin E, which lacks proven efficacy 1)
• Normal arterial flow (no arterial insufficiency)

Why PDE-5 Inhibitor is the Correct Choice

Addresses Both Conditions Simultaneously

According to the 2025 EAU guidelines, PDE-5 inhibitors serve dual purposes in this clinical scenario 1:

1. For Erectile Dysfunction: PDE-5 inhibitors are first-line therapy for ED, including cases with mild venous leak 1

2. For Peyronie's Disease: Daily tadalafil 5 mg demonstrated:

   • Lower curvature progression rates versus controls
   • Improved symptoms
   • May reduce collagen deposition and increase apoptosis in Peyronie's disease 1

Why Not the Other Options?

B. Intracavernous pharmacotherapy: This is second-line therapy, reserved for PDE-5 inhibitor failures 1. Starting here bypasses the safer, less invasive first-line option.

C. Corporal plication (tunical shortening): Surgery requires stable disease for 3-6 months and is indicated when conservative treatments fail 1. This patient hasn't tried effective medical therapy yet. Additionally, plication is typically reserved for curvature that precludes intercourse, and this patient has <30° curvature.

D. Plaque incision and grafting (tunical lengthening): The 2025 EAU guidelines specifically state this is recommended for patients with severe shortening, curvature >60°, or complex deformities, WITHOUT ED 1. This patient has <30° curvature and has ED, making him a poor candidate. Furthermore, these procedures carry up to 50% risk of postoperative ED 1.

E. Penile prosthesis surgery: The guidelines clearly state that penile prosthesis implantation is indicated for Peyronie's disease patients with concurrent ED unresponsive to medical therapy 1. This patient hasn't tried appropriate medical therapy (PDE-5 inhibitors) yet.

Treatment Algorithm

1. First-line: Oral PDE-5 inhibitor (daily tadalafil 5 mg preferred for Peyronie's disease) 1
2. If inadequate response: Consider combination therapy (PDE-5 inhibitor + intracavernous alprostadil) or penile traction therapy as adjunct 1
3. If medical therapy fails: Surgical options based on erectile function status and curvature severity 1

Critical Pitfalls to Avoid

• Don't jump to surgery without attempting effective medical therapy first
• Vitamin E is not effective - the guidelines explicitly state oral treatments including vitamin E "are not recommended due to lack of proven efficacy" and "may delay more effective interventions" 1
• Don't perform tunical lengthening procedures in patients with ED - these carry high ED risk (up to 50%) and are contraindicated when ED is already present 1
• Recognize that mild venous leak doesn't preclude PDE-5 inhibitor success - these medications work through multiple mechanisms and remain first-line therapy

The patient's mild venous leak is not a contraindication to PDE-5 inhibitors, which remain the appropriate initial management for his combined erectile dysfunction and stable Peyronie's disease.